There are quite a few ASX shares that may still be solid ideas to consider for the long-term, despite the strong run of the ASX share market.
Companies that are expecting to deliver a high level of earnings growth over the next few years may be able to positively surprise investors.
Businesses that are growing across the world may be even more compelling.
Here are two ASX shares to consider:
Webjet Limited (ASX: WEB)
Webjet is one of the leading global travel companies.
The company is still being impacted by COVID-19 effects, but it's expecting to return to profitability as domestic and international travel resumes.
With WebBeds, the business to business part of the company, it has an ongoing transformation strategy to emerge as the global number one provider.
Webjet believes it's going to achieve positive operating cashflow in the first half of FY22 after reducing costs and becoming more efficient.
Management think the company is on track to be at least 20% more cost-efficient at scale, suggesting a "significant" leverage opportunity. When markets normalise, Webjet says that WebBeds will have greater market share, lower costs and improved profitability.
Previously, Webjet was targeting a Webjet earnings before interest, tax, depreciation and amortisation (EBITDA) margin of 50%. But now management think that it can reach a 62.5% margin because of those cost savings.
The ASX share also believes that it can take increasing domestic market share, with a growing presence by its online travel agency (OTA) segment. Its advantages include the accelerating structural shift to online and a "superior" technology offering. It now has a 11.3% market share, up from 5.6% in April 2020.
Australia's domestic and international borders are now opening up, opening the gates to more volume.
It's currently rated as a buy by UBS, with a price target of $6.85.
Doctor Care Anywhere Group PLC (ASX: DOC)
Doctor Care Anywhere is a UK-based telehealth business that wants to provide the best care possible through digitally-enabled, joined up, evidence-based pathways with its platform. It works with health insurers, healthcare providers and corporate customers.
The business continues to scale quickly.
Last month it released its quarterly numbers for the three months to 30 September 2021.
It said that revenue grew quarter on quarter by 21.6% to £5.8 million. This was driven by 30.6% quarter on quarter growth of consultations to 116,800. A record 41,000 patients had their first ever Doctor Care Anywhere consultation during the quarter, while more than 65% of consultations were delivered to returning patients.
There was also continued progress in joining up patient pathways, with 5,100 patients completing the secondary care diagnostic pathway – this was growth of 54.5%.
The ASX share is working on overseas expansion. It has completed the acquisition of Australian tele-health and tele-mental provider, GP2U Telehealth.
Doctor Care Anywhere has also entered the self-pay market in the Republic of Ireland through channel partner Boots.
Management expect that the company can grow its FY21 revenue by at least 100% compared to FY22. Its financial year lines up with the calendar year.
Doctor Care Anywhere says that not only is its solution more convenient for patients, but it is also demonstrating value for doctors and insurers by removing inefficiencies and reducing costs throughout the patient journey, The company is expecting higher profit margins as the pandemic effects ease on the UK clinical workforce.
Taking steps to improve profit margins above pre-COVID levels remains a "key focus" for the company.
